Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 185

Similar articles for PubMed (Select 24281161)

1.

The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.

Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K, Fabarius A, Teichmann M, Schneider S, Ernst T, Müller MC, Giehl M, Marx A, Hartmann K, Hochhaus A, Hofmann WK, Cross NC, Reiter A.

Ann Hematol. 2014 Jan;93(1):81-8. doi: 10.1007/s00277-013-1964-1. Epub 2013 Nov 27.

PMID:
24281161
2.

Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.

Kristensen T, Broesby-Olsen S, Vestergaard H, Bindslev-Jensen C, Møller MB; Mastocytosis Centre Odense University Hospital.

Eur J Haematol. 2013 Aug;91(2):106-11. doi: 10.1111/ejh.12128. Epub 2013 Jun 28.

PMID:
23621866
3.

The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.

De Matteis G, Zanotti R, Colarossi S, De Benedittis C, Garcia-Montero A, Bonifacio M, Sartori M, Aprili F, Caruso B, Paviati E, Carli G, Perbellini O, Zamò A, Bonadonna P, Pizzolo G, Guidi G, Martinelli G, Soverini S.

Leuk Res. 2015 Mar;39(3):273-8. doi: 10.1016/j.leukres.2014.11.029. Epub 2014 Dec 6.

PMID:
25582384
4.

High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.

Fritsche-Polanz R, Fritz M, Huber A, Sotlar K, Sperr WR, Mannhalter C, Födinger M, Valent P.

Mol Oncol. 2010 Aug;4(4):335-46. doi: 10.1016/j.molonc.2010.04.008. Epub 2010 Apr 24.

5.

The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.

Hoermann G, Gleixner KV, Dinu GE, Kundi M, Greiner G, Wimazal F, Hadzijusufovic E, Mitterbauer G, Mannhalter C, Valent P, Sperr WR.

Allergy. 2014 Jun;69(6):810-3. doi: 10.1111/all.12409. Epub 2014 Apr 17.

PMID:
24750133
6.

Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.

Sotlar K, Bache A, Stellmacher F, Bültmann B, Valent P, Horny HP.

J Mol Diagn. 2008 Jan;10(1):58-66. doi: 10.2353/jmoldx.2008.070061. Epub 2007 Dec 28. Erratum in: J Mol Diagn. 2009 May;10(3):276.

7.

Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.

Kristensen T, Vestergaard H, Møller MB.

J Mol Diagn. 2011 Mar;13(2):180-8. doi: 10.1016/j.jmoldx.2010.10.004.

8.

In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.

Böhm A, Sonneck K, Gleixner KV, Schuch K, Pickl WF, Blatt K, Peter B, Herrmann H, Schernthaner GH, Pehamberger H, Rabitsch W, Sperr WR, Valent P.

Exp Hematol. 2010 Sep;38(9):744-55. doi: 10.1016/j.exphem.2010.05.006. Epub 2010 May 27.

PMID:
20553795
9.

Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).

Sotlar K, Colak S, Bache A, Berezowska S, Krokowski M, Bültmann B, Valent P, Horny HP.

J Pathol. 2010 Apr;220(5):586-95. doi: 10.1002/path.2677.

PMID:
20112369
10.

KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.

Broesby-Olsen S, Kristensen T, Vestergaard H, Brixen K, Møller MB, Bindslev-Jensen C; Mastocytosis Centre Odense University Hospital (MastOUH).

J Allergy Clin Immunol. 2013 Sep;132(3):723-8. doi: 10.1016/j.jaci.2013.02.019. Epub 2013 Apr 12.

PMID:
23587333
11.

Mastocytosis: state of the art.

Horny HP, Sotlar K, Valent P.

Pathobiology. 2007;74(2):121-32. Review.

PMID:
17587883
12.

Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR.

Schumacher JA, Elenitoba-Johnson KS, Lim MS.

J Clin Pathol. 2008 Jan;61(1):109-14. Epub 2007 May 25.

PMID:
17526803
13.

Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.

Pardanani A.

Am J Hematol. 2012 Apr;87(4):401-11. doi: 10.1002/ajh.23134. Review.

PMID:
22410759
14.

Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.

Wang SA, Hutchinson L, Tang G, Chen SS, Miron PM, Huh YO, Jones DM, Bueso-Ramos C, Verstovsek S, Medeiros LJ, Miranda RN.

Am J Hematol. 2013 Mar;88(3):219-24. doi: 10.1002/ajh.23380.

15.

Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.

Corless CL, Harrell P, Lacouture M, Bainbridge T, Le C, Gatter K, White C Jr, Granter S, Heinrich MC.

J Mol Diagn. 2006 Nov;8(5):604-12.

16.

Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.

Ustun C, Corless CL, Savage N, Fiskus W, Manaloor E, Heinrich MC, Lewis G, Ramalingam P, Kepten I, Jillella A, Bhalla K.

Leuk Res. 2009 May;33(5):735-41. doi: 10.1016/j.leukres.2008.09.027. Epub 2008 Nov 4.

PMID:
18986703
17.

Comprehensive mutational profiling in advanced systemic mastocytosis.

Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NC, Reiter A.

Blood. 2013 Oct 3;122(14):2460-6. doi: 10.1182/blood-2013-04-496448. Epub 2013 Aug 19.

18.

ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.

Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D, Kolb B, Durieu I, Gyan E, Livideanu C, Chèze S, Diouf M, Garidi R, Georgin-Lavialle S, Asnafi V, Lhermitte L, Lavigne C, Launay D, Arock M, Lortholary O, Dubreuil P, Hermine O.

PLoS One. 2014 Jan 21;9(1):e85362. doi: 10.1371/journal.pone.0085362. eCollection 2014.

19.

Systemic mastocytosis: progressive evolution of an occult disease into fatal mast cell leukemia: unique findings on an unusual hematological neoplasm.

Gülen T, Sander B, Nilsson G, Palmblad J, Sotlar K, Horny HP, Hägglund H.

Med Oncol. 2012 Dec;29(5):3540-6. doi: 10.1007/s12032-012-0261-5. Epub 2012 Jun 3.

PMID:
22661384
20.

Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.

Pardanani A.

Am J Hematol. 2015 Mar;90(3):250-62. doi: 10.1002/ajh.23931. Review.

PMID:
25688753
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk